| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6001058 | Thrombosis Research | 2015 | 4 Pages |
Abstract
Prolonging the treatment with lower doses of aPCC beyond the initial phase in patients with AHA in whom the titre of FVIII inhibitor is still high is likely to safely prevent further bleeding complications.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Ezio Zanon, Marta Milan, Gabriella Gamba, Chiara Ambaglio, Graziella Saggiorato, Luca Spiezia, Nadia Montani, Paolo Prandoni,